tebentafusp

Home
Ligands
tebentafusp

GtoPdb Ligand ID: 7378

Synonyms: IMCgp100 | Kimmtrak® | tebentafusp-tebn

tebentafusp is an approved drug (FDA & EMA (2022))

Comment: Tebentafusp (IMCgp100) is an immunotherapeutic antibody/peptide fusion, comprising a soluble T cell receptor (TCR) specific for the HLA-A2 restricted melanoma-associated antigen gp100, fused to an anti-CD3 single chain antibody fragment (scFv) [1,3-4]. This belongs to a novel class of immunotherapeutics termed ImmTACs (Immune Mobilising mTCR against Cancer) which are designed to restore immune surveillance and T-cell-directed killing of specific cancer cells.

No information available.

No information available.

Summary of Clinical Use
Tebentafusp (IMCgp100) was investigated in clinical trials as a novel treatment for advanced stage malignant uveal melanoma. Preliminary results of Phase 1/2 trials demonstrated that the therapy was well tolerated and tumour volume reduction was observed in some patients [5]. Click here to link to ClinicalTrials.gov's complete list of clinical trials assessing IMCgp100 as a cancer treatment. Following a positive Phase 3 trial [6], tebentafusp was FDA approved in January 2022, as a therapy for unresectable or metastatic uveal melanoma.

Summary of Clinical Use

Tebentafusp (IMCgp100) was investigated in clinical trials as a novel treatment for advanced stage malignant uveal melanoma. Preliminary results of Phase 1/2 trials demonstrated that the therapy was well tolerated and tumour volume reduction was observed in some patients [5]. Click here to link to ClinicalTrials.gov's complete list of clinical trials assessing IMCgp100 as a cancer treatment. Following a positive Phase 3 trial [6], tebentafusp was FDA approved in January 2022, as a therapy for unresectable or metastatic uveal melanoma.